Stability and sterility of recombinant tissue plasminogen activator at -30 degrees C.
We assessed whether frozen recombinant tissue plasminogen activator (rt-PA) remains stable and sterile for up to 22 weeks at -30 degrees C. Our findings confirm that rt-PA is a cost-effective alternative to urokinase for restoring patency to occluded central venous catheters.
Wiernikowski
J T
JT
Crowther
M
M
Clase
C M
CM
Ingram
A
A
Andrew
M
M
Chan
A K
AK
D002405:Catheterization, Central Venous / Q000009:adverse effects / Q000295:instrumentation; D002408:Catheters, Indwelling / Q000009:adverse effects; D003362:Cost-Benefit Analysis; D004340:Drug Contamination / Q000517:prevention & control; D004355:Drug Stability; D005615:Freezing; D006801:Humans; D010960:Plasminogen Activators / Q000737:chemistry* / Q000191:economics; D011994:Recombinant Proteins; D015912:Thrombolytic Therapy; D013927:Thrombosis / Q000188:drug therapy; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000737:chemistry* / Q000191:economics; D014568:Urokinase-Type Plasminogen Activator / Q000191:economics / Q000627:therapeutic use
D011994:Recombinant Proteins; D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator